Tagged with france

France Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From our roots as a French company, we have blossomed into a growing international player within the areas of oncology, neuroscience and…

France Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of the French biological research ecosystem, public-private partnerships, and post-Brexit France.  The CNRS has activity in nearly every field of science…

France Eric Bothorel, Deputy at the French Assemblée Nationale and responsible for the parliamentary group on data, knowledge & AI, provides an exclusive interview on France’s digitalization process. Bothorel describes France’s progress in frontier technologies like AI and Big Data and explains their expanding role in the healthcare sector.   Can…

France Dr. Julien Borowczyk, Secretary of the Social Affairs Commission at the French Assemblée Nationale, offers his insights on the upcoming changes to the French healthcare system. He walks our audience through France’s toughest healthcare problems, the recent Conseil stratégique des industries de santé (CSIS), and the potential for AI and…

France Genethon, a laboratory created by the patient organization AFM-Telethon, is one of the world’s leaders in the development of biotherapies for rare diseases. In this interview Genethon’s CEO Frédéric Revah explains its role in the discovery of innovative therapies since the 1990s and the recent launch of YposKesi, its innovative…

France Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds of change in the sector after the establishment of the Macron government, the 2018 Strategic Council of Health Industries (CSIS) and new pro-industry measures. I believe that we can make France a worldwide leader in…

France Jacques Vernin, president of FACOPHAR Santé – the French association representing companies involved in the natural and herbal health space, explains its role and the future of the organization in participating in social dialogue, shaping regulations and promoting French excellence in the field of herbal ingredients.   Could you please…

France Prof. Alexis Brice, director of the French Brain & Spine Institute (Institut du Cerveau et de la Moelle épinière (ICM)), reveals the recipe behind the success of the center since its foundation eight years ago and discusses the future of research on neurodegenerative diseases.   Could you please introduce your…

France Emmanuel Eumont, general manager of Gedeon Richter France, discusses the group’s leading position in women’s health, its external growth strategy, notably through the acquisition of Finox Biotech in 2016, and the upcoming product launches that will strengthen its portfolio. Finally, Eumont shares his thoughts on the 8th edition of the…

France Key statistics on the workforce, revenue, investment levels, R&D spending and consumption in the French pharmaceutical industry today. Mapping the 32 biopharma production sites in France, including the location, company and products produced. France ranks fourth in the EU for pharma production with EUR 20.981 billion in value, behind Switzerland,…

Regulation Dominique Martin, CEO of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) provides a fascinating insight into the French process of authorizing drugs and medical products, his commitment to increased transparency and increased efficiency, and the opportunity for France to take the lead in European…

France Dr. Denis Comet, President of AFCRO (the French Association of CROs), talks about the evolution of the clinical research environment in France and the new government actions aimed at speeding up the clinical trial process.   Didier Genot from France Biotech told us that France has lost competitiveness when it…